Biofilm Pharma was founded in 2017 as a part of the Biofilm Technologies Group.
Biofilm Pharma benefits from the experience, technological leadership and patents of the Biofilm Technologies Group in its efforts of discovering and designing the future of antimicrobial drugs.
Thierry BERNARDI, CEO of Biofilm Pharma
Severe and chronic infections are now known to be caused by bacterial biofilms, a bacterial behavior which promotes adhesion to a surface and improves antimicrobial resistance.
When it comes to cure biofilm infections existing antibiotics therapies are ineffective.
At Biofilm Pharma, we have an innovative approach, based on products which prevent bacterial adhesion (antibiofilm) without killing bacteria (non antibiotic) and thus preserving the positive microbiote.
Biofilm Pharma uses its proprietary High Troughput Screening robotic platform in an unprecedented screening campaign of antimicrobial molecules with an anti-biofilm added value.
Our screening is unique thanks to the use of a patented technology of the Biofilm Technologies Group : the Biofilm Ring Test®. This technology is the only one to focus on bacterial adhesion, in a reliable and standardized way.
We are the only ones to have access to this information : that’s the Biofilm Pharma advantage !!!
BFP001 : Antibiofilm non antibiotic. Indications : Local, Diabetic Foot Ulcer, Joint & Bone Infections
BFP002 : Antibiofilm non antibiotic. Indications : Cystic Fibrosis
BFP101 : Antibiofilm antibiotic. Indications : Local, Diabetic Foot Ulcer, Joint & Bone Infections
BFP102 : Antibiofilm antibiotic. Indications : Cystic Fibrosis
Biofilm Pharma has already financed its first project of antimicrobial treatments.
We are still searching for new investments and partnerships to develop our panel of drug candidates targeting chronic infections.
Seize the opportunity
to access an unexplored pharmaceutical market and being a pioneer in the new world of antimicrobials.
